* Microcide Pharmaceuticals Inc., of Mountain View, Calif., receiveda $1 million milestone payment from Johnson & Johnson, of NewBrunswick, N.J., in their collaboration on development of a candidatecompound for treatment of gram-positive bacteria that have becomeresistant to current antibiotics. The two companies begancollaborating on development of new antibiotics in October 1995.
* Myriad Genetics Inc., of Salt Lake City, began genetic testing forearly-onset hereditary breast cancer and ovarian at the end of October1996. The diagnostics are based on the company's discoveries of theBRCA1 and BRCA2 breast cancer genes. The fee for the genetictesting, which takes 10 days to complete, is $2,400 plus an additional$395 for detailed analysis of specific mutations.
(c) 1997 American Health Consultants. All rights reserved.